Use of AP-1 activators to treat glaucoma and ocular hypertension

Abstract

Compositions comprising AP-1 activators and methods of use for treating glaucoma and ocular hypertension are disclosed.

1 . A topical composition for treating glaucoma or ocular hypertension comprising an AP-1 Activator and a pharmaceutically acceptable vehicle.  
     
     
         2 . A composition according to  claim 1 , wherein the AP-1 Activator is selected from the group consisting of: β-naphthoflavone, tert-butylhydroquinone, and sulpiride.  
     
     
         3 . A composition according to  claim 2 , wherein the AP-1 Activator is tert-butylhydroquinone.  
     
     
         4 . A composition according to  claim 1 , wherein the composition comprises: 
 about 0.01 to 2.0% w/v t-HBQ;    about 0.28% w/v sodium phosphate;    about 0.8% w/v sodium chloride;    about 0.01% w/v benzalkonium chloride about 0.5% w/v HPMC;    about 0.1% w/v edetate disodium; and water    
     
     
         5 . A method for treating glaucoma or ocular hypertension which comprises administering to a mammal a composition comprising an AP-1 Activator and a pharmaceutically acceptable vehicle.  
     
     
         6 . A method according to  claim 5 , wherein the AP-1 Activator is selected from the group consisting of: β-naphthoflavone, tert-butylhydroquinone, and sulpiride.  
     
     
         7 . A method according to  claim 6 , wherein the AP-1 Activator is tert-butylhydroquinone.  
     
     
         8 . A method according to  claim 5 , wherein the composition comprises: 
 about 0.01 to 2.0% w/v t-HBQ;    about 0.28% w/v sodium phosphate;    about 0.8% w/v sodium chloride;    about 0.01% w/v benzalkonium chloride    about 0.5% w/v HPMC;    about 0.1% w/v edetate disodium; and water.